SELLAS Q2 Cash Rises to $138.3M but REGAL Event Silence and SLS009 Expansion Shift Risk/Reward

What happened

SELLAS reported $138.3 million in cash as of June 30, 2026, a significant increase from $107.1 million at the end of Q1, but did not comment on the source or any stock sales under its $150 million ATM program. The company provided no update on the REGAL Phase 3 event count, which stood at 78 of 80 as of May 11, implying the final analysis trigger has likely not been met, increasing timeline risk ahead of the pivotal readout. Meanwhile, 28 patients have been enrolled into the Phase 2 first-line AML trial of SLS009, with topline data still on track for Q4 2026, and management highlighted preclinical work in pancreatic cancer as a new expansion opportunity. The lack of a REGAL event announcement now pushes the catalyst window beyond earlier expectations, while the unexplained cash build—possibly from warrant exercises or undisclosed ATM usage—renews dilution concerns that the master report flagged as a key downside risk. Overall, the update reinforces a patient-challenging event trajectory and keeps the financing overhang squarely in focus, tilting the near-term risk/reward further negative despite operational progress.

Implication

The extended REGAL timeline and absence of event disclosure weaken the near-term catalyst thesis, while the cash increase without transparency fuels dilution fears. With SLS009 data not due until Q4 2026, the stock may drift lower absent a definitive REGAL trigger, and any ATM usage would materially compress per-share value. Investors should await either a confirmed 80th event announcement or evidence that the ATM remains untapped before adding exposure, and set a hard stop on further delays or adverse financing disclosures.

Thesis delta

The thesis delta is negative: the REGAL event count appears stalled, pushing the catalyst beyond the prior window and validating the master report’s concern about timing uncertainty. The cash build, if from ATM sales, would indicate management’s preference for dilution over debt, undermining the bull case. Confidence in a near-term positive binary outcome is therefore reduced.